The Journal of dermatological treatmentHumansPruritusChronic DiseaseAntibodiesMonoclonal
Nemolizumab for chronic pruritus beyond atopic dermatitis and prurigo nodularis: a systematic review and synthesis of emerging evidence.
Mohammed Shanshal, Aarthy Uthayakumar
Published: 202610.1080/09546634.2026.2612882
Abstract
BACKGROUND: Nemolizumab, an anti-IL-31 receptor A antibody, is licensed for atopic dermatitis and prurigo nodularis; its role in other chronic pruritus (CP) syndromes is uncertain. OBJECTIVE: To synthesize efficacy, safety and strength of evidence fo…
Preview only. Read the full abstract at the source